Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain - Full Text View

Sponsors and Collaborators:	University of Heidelberg Central Institute of Mental Health, Mannheim University of Mannheim Academic City Hospital, Germany BG-clinics Ludwigshafen Germany
Information provided by:	University of Heidelberg
ClinicalTrials.gov Identifier:	NCT00176163

Purpose

It is known, that a so called “pain memory” usually evolves in chronic pain syndromes which both aggravates the disorder and modifies the patients pain perception. Thus, the principal object of pain therapy is to “delete” this dysfunctional pain memory. The combination of medication, physiotherapy and psychological therapy seems to be the most effective treatment. This study investigates the effect of a concomitant Dronabinol medication (Cannabinoid) on the effectiveness of behavioral therapy. It is hypothesized that the combination of behavioral therapy and Dronabinol will be most effective in deleting the pain memory.

Condition	Intervention	Phase
Fibromyalgia Back Pain	Behavioral: Operant behavioral treatment; Drug: THC	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Official Title:	Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain

Resource links provided by NLM:

MedlinePlus related topics: Back Pain Fibromyalgia

Drug Information available for: Tetrahydrocannabinol

U.S. FDA Resources

Further study details as provided by University of Heidelberg:

Primary Outcome Measures:

Impairment by pain

Secondary Outcome Measures:

Pain intensity
physical function and emotional state assessed by questionnaires
number of serious adverse events
subjective rating of improvement by therapy
subjective rating of therapy effectiveness
therapy satisfaction rated by patient

Estimated Enrollment:	240
Study Start Date:	August 2005
Estimated Study Completion Date:	August 2008

Detailed Description:

This study investigates the combination of operant behavioral treatment and Cannabinoid medication in patients with fibromyalgia and patients with back pain. It is well known that cannabinoids (THC) accelerate learning processes. It is assumed that the combination of both treatments may exert an synergetic effect. A low dose of THC is used, which ist not expected to have direct analgetic effects. The study also investigates genetic determinants of both disorders and the response to treatment, respectively.

The patients will be randomly assigned to one of four groups: Behavioral therapy and Dronabinol, behavioral therapy and placebo, behavioral therapy only, standard medical therapy. Patients will attend 12 weekly group-sessions (6-8 patients) of behavioral therapy. Behavioral therapy sessions will include training in reducing pain behaviour and establishing active and “healthy” behaviour instead. There will be weekly medical safety visits, in which the patients receive medication and undergo a physical examination (blood and urine samples).

Patients will be evaluated before and after behavioral therapy and will be followed for an additional 6- and 12-months phase. The outcome variables will be recorded by the use of interviews and questionnaires.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of Fibromyalgia meeting ACR-criteria
Diagnosis of chronic back pain
Pain duration exceeding 3 months
Age between 18 and 70 years
The patient has been informed about the study, understood the information and signed the informed consent form

Exclusion Criteria:

Tumors, fractures and heavy osteoporosis
Secondary back pain at arthrosis or degenerative scoliosis
Radicular back pain
Other pain syndrome is main problem
Opiate medication > 60mg morphine per diem
Addiction (drugs, alcohol, medicaments)
Cardiac insufficiency > NYHA II
Exercise induced dyspnea, Angina pectoris A detailed version of exclusion criteria: see study protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00176163

Contacts

Contact: Christoph Konrad, MD, PhD

0049 621 383 2608

christoph.konrad@anaes.ma.uni-heidelberg.de

Locations

Germany, BaWü
University Hospital	Recruiting
Mannheim, BaWü, Germany, 68167
Contact: Christoph Konrad, MD, PhD 0049 621 383 2608 christoph.konrad@anaes.ma.uni-heidelberg.de
Principal Investigator: Christoph Konrad, MD, PhD

Sponsors and Collaborators

University of Heidelberg

Central Institute of Mental Health, Mannheim

University of Mannheim

Academic City Hospital, Germany

BG-clinics Ludwigshafen Germany

Investigators

Study Director:

Christoph Konrad, MD, PhD

University of Heidelberg

More Information

No publications provided

Study ID Numbers:	kfg107
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00176163 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Heidelberg:

Fibromyalgia
Back pain
Behavior Therapy
Operant learning
Tetrahydrocannabinol

Study placed in the following topic categories:

Fibromyalgia
Myofascial Pain Syndromes
Psychotropic Drugs
Pain
Rheumatic Diseases
Back Pain
Tetrahydrocannabinol
Signs and Symptoms

Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Analgesics, Non-Narcotic
Neurologic Manifestations
Peripheral Nervous System Agents
Analgesics

Additional relevant MeSH terms:

Fibromyalgia
Myofascial Pain Syndromes
Physiological Effects of Drugs
Nervous System Diseases
Psychotropic Drugs
Hallucinogens
Pain
Rheumatic Diseases
Back Pain
Pharmacologic Actions
Tetrahydrocannabinol

Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Neurologic Manifestations
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009